API

The global API market is entering a new growth cycle in 2026, driven by the patent cliff, aging populations, and breakthroughs in GLP-1 and nucleic-acid therapies, while China's API industry accelerates its shift toward innovation and green manufacturing.

China's API sector is approaching a historic turning point as supply-chain restructuring, industry consolidation and innovation-driven demand converge, setting the stage for a valuation re-rating from 2026.

China's chemical API industry is at a pivotal turning point, where global leadership built on scale is giving way to an innovation-driven upgrade that will redefine its role in the global pharmaceutical supply chain.

Eli Lilly will invest over US$6 billion to build a new pharmaceutical manufacturing facility in Huntsville, Alabama, expanding its US production footprint.

China's API sector is shifting from a ‘price war' to a ‘value war' amid global supply chain restructuring, signaling resilience and renewed growth momentum.